Today: 1 July 2026
Browse Category

NYSE:SNY 16 September 2025 - 17 January 2026

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

New York, Jan 15, 2026, 13:24 EST — Regular session Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands.
15 January 2026
····
Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Dynavax Technologies Corporation is the standout mover heading into the Christmas break after Sanofi agreed to acquire the vaccine maker in an all-cash deal valued at about $2.2 billion. The transaction price — $15.50 per share in cash — instantly re-framed DVAX from a “biotech fundamentals” story into a deal-arbitrage stock, with trading now anchored around the buyout price. Reuters+2PR Newswire+2 A timing note that matters for anyone planning “tomorrow” trades: U.S. equities had a holiday early close today at 1:00 p.m. ET, and the market is closed Thursday, Dec. 25 for Christmas. The next regular U.S. equity session is Friday, Dec. 26. NASDAQ Trader+1
24 December 2025
··
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies Corporation is the center of the biotech tape on Wednesday, December 24, 2025, after Sanofi announced a deal to acquire the vaccine maker in an all-cash transaction valued at roughly $2.2 billion. The headline number investors are keying on: $15.50 per share in cash—a bid that reframes the near-term outlook for DVAX stock from “earnings and pipeline execution” to “deal timeline and closing risk.” Sanofi+1 Below is what’s driving today’s move, how the market is pricing the deal so far, what Wall Street forecasts looked like before the announcement, and the key dates and risks investors will likely track next.
24 December 2025
···
EU Stock Markets Today (24 December 2025): STOXX 600 Flat on Christmas Eve as BP Castrol Deal, Sanofi’s Dynavax Move and Record Metals Set the Tone

EU Stock Markets Today (24 December 2025): STOXX 600 Flat on Christmas Eve as BP Castrol Deal, Sanofi’s Dynavax Move and Record Metals Set the Tone

EU stock markets traded in a distinctly “holiday mode” on Wednesday, December 24, 2025, with liquidity thinning sharply as several exchanges either closed entirely or ran shortened sessions for Christmas Eve. The STOXX 600—a widely followed pan-European benchmark that investors often use as a proxy for the region—was flat at 588.93 by 08:09 GMT, pausing after a run of fresh highs earlier in the week. Reuters The muted headline move, however, masked a handful of themes that still mattered to investors positioning into year-end: energy shares were supported by firmer oil, miners followed another surge in precious metals, and large-cap deal news brought individual names back into focus—even in a shortened session. Reuters+2Reuters+2
24 December 2025
···
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3 Below is a comprehensive roundup of the most market-moving healthcare news, plus the latest forecasts and sector analysis shaping how investors are positioning across pharma, biotech, managed care, medtech, and healthcare services into 2026.
20 December 2025
········
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost. Scale and Scope: The plant will include over 200,000 square feet of production space Virginiabusiness, equipped with cutting-edge technologies like machine learning, artificial intelligence, and automation to ensure precision and efficiency Prnewswire. Construction is beginning immediately and expected to take about five years to fully complete Washingtonpost – a timeline Lilly hopes to beat if possible, according to CEO David “Dave” Ricks Virginiabusiness. Initial site work and permitting are starting within weeks, and Lilly aims to have the physical plant built in about three years, then undergo equipment validation and regulatory approvals Virginiabusiness. “The typical timeline…is five years…so we’d like to beat that,” Ricks said, noting Lilly is working with federal regulators to speed up
16 September 2025
·······

Stock Market Today

  • Japan Moves to Defend Yen, Spends $74 Billion as Dollar Stays Strong
    July 1, 2026, 2:31 AM EDT. Japan logged nearly $74 billion in currency intervention as the yen sank to a 40-year low against the dollar. The country's latest move comes as the Bank of Japan raised rates to 1%, but that's still nowhere near U.S. levels, and the dollar keeps the upper hand. Traders say Tokyo's solo efforts face tough odds with the Fed sticking to higher rates. Some say a joint response with the U.S. might help, but the yen's latest slide is more about the rallying dollar than doubt in Japan itself. The popular carry trade-borrowing yen to chase returns in the U.S.-adds to the pressure.
Go toTop